Yanira Sáez-Álvarez

Yanira Sáez-Álvarez

Auto-generated profile, based on publicly available information

Yanira Sáez-Álvarez

Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
YÁYanira Sáez Álvarez
Yanira Sáez Álvarez
NONereida Jiménez de Oya
Nereida Jiménez de Oya
CÁCarmen del Águila
Carmen del Águila
Juan Carlos SaizJuan Carlos Saiz
Juan Carlos Saiz
AAArmando Arias
Armando Arias
Miguel Martin-AcebesMiguel Martin-Acebes
Miguel Martin-Acebes
Zika virus (ZIKV) is a mosquito-borne pathogen responsible for neurological disorders (Guillain-Barré syndrome) and congenital malformations (microcephaly). Its ability to cause explosive epidemics, such as that of 2015 to 2016, urges the identification of effective antiviral drugs.

24 February 2023 in Antiviral Research
Verified
Journal Article
Open access
MGMarta García-Zarandieta
Marta García-Zarandieta
EQErnesto Quesada
Ernesto Quesada
MMMaría I. Martínez-Jiménez
María I. Martínez-Jiménez
CNCristina V. Newnes
Cristina V. Newnes
VFVictor Fernández-Cabello
Victor Fernández-Cabello
RTRubén Agudo Torres
Rubén Agudo Torres
West Nile virus (WNV) is a re-emergent mosquito-borne RNA virus that causes major outbreaks of encephalitis around the world. However, there is no therapeutic treatment to struggle against WNV, and the current treatment relies on alleviating symptoms. Therefore, due to the threat virus poses to animal and human health, there is an urgent need to come up with fast strategies to identify and assess effective antiviral compounds. A relevant target when developing drugs against RNA viruses is the viral RNA-dependent RNA polymerase (RdRp), responsible for the replication of the viral genome within a host cell. RdRps are key therapeutic targets based on their specificity for RNA and their essential role in the propagation of the infection. We have developed a fluorescence-based method to measure WNV RdRp activity in a fast and reliable real-time way. Interestingly, rilpivirine has shown in our assay inhibition of the WNV RdRp activity with an IC50 value of 3.3 μM and its antiviral activity was confirmed in cell cultures. Furthermore, this method has been extended to build up a high-throughput screening platform to identify WNV polymerase inhibitors. By screening a small chemical library, novel RdRp inhibitors 1-4 have been identified. When their antiviral activity was tested against WNV in cell culture, 4 exhibited an EC50 value of 2.5 μM and a selective index of 12.3. Thus, rilpivirine shows up as an interesting candidate for repurposing against flavivirus. Moreover, the here reported method allows the rapid identification of new WNV RdRp inhibitors.

10 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
JMJosé Carlos Estanislao Márquez Montesinos
José Carlos Estanislao Márquez Montesinos
ABAna Bernárdez
Ana Bernárdez
YMYuliet Mazola
Yuliet Mazola
LVLucianna Vaccaro
Lucianna Vaccaro
YÁYanira Sáez Álvarez
Yanira Sáez Álvarez
CMCAROLINA HURTADO MARCOS
CAROLINA HURTADO MARCOS
Aptamer development has traditionally relied on iterative, labor-intensive experimental approaches. Recent advances in bioinformatics and computational power now enable the rational in silico design of high-affinity nucleic acid ligands, drastically reducing time and cost. Here, we present an integrated computational pipeline for designing ssDNA aptamers targeting the receptor-binding domain (RBD) of the SARS-CoV-2 Spike (S) protein. A library of 4000 randomly generated 20-nucleotide sequences with defined base ratios (C:G:A:T = 3:3:2:2) was screened based on secondary structure and free energy. The 100 most stable sequences (ΔG ≤ −4.1 kcal/mol) were modeled in three dimensions, yielding 1000 conformations. The 100 structures with the lowest potential energies (≤−78,051.7 kcal/mol) were selected for molecular docking with the RBD in the closed, open, and transitional states. Two aptamers—model-2-seq_2714 (seq_2714) and model-5-seq_1397 (seq_1397)—were selected for experimental assessment based on their favorable predicted docking scores against the RBD. Western blot and dot blot assays showed detectable recognition of the recombinant RBD by both aptamers under the experimental conditions tested. Exploratory testing in a limited number of clinical and environmental samples further showed that detectable signals could be obtained in selected complex matrices. These findings provide an initial proof-of-principle assessment of a computational-first strategy for prioritizing candidate aptamers for subsequent experimental testing.